Correlation Between Mild Cognitive Impairment and Levodopa Induced Dyskinesia in Parkinson’s Disease Patients
Objective: The aim of this study is to compare the level of mild cognitive impairment in Parkinson’s disease patients with and without levodopa-induced dyskinesia. Additionally,…Clinical benefit of Opicapone in patients with different Parkinson disease phenopytes. The OPTIMO study
Objective: To assess the clinical benefit induced by opicapone (OPC) as an add-on therapy to levodopa in fluctuating Parkinson’s disease (PD) patients with special focus…Abnormal Subthalamic Oscillations as Potential Biomarkers for Identifying the Dyskinesia-Inducing Region within the Subthalamic Nucleus in Parkinson’s Disease
Objective: To investigate the characteristics of local field potentials (LFPs) associated with the STN region that elicit stimulation-induced dyskinesia (SID) in PD patients. Background: Approximately 50%…Prevalence of Helicobacter Pylori Infection Among Nepalese Parkinson’s Disease Patients and their Clinical Manifestations
Objective: To know the prevalence of Helicobacter Pylori infection among Nepalese Parkinson´s Disease patients and understand their clinical characteristics Background: Helicobacter pylori (HP) is prevalent…Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…Altered EEG Theta Activity Characterizes Parkinson’s disease with Levodopa-induced Dyskinesia
Objective: We explored the relationship between the build-up and the downscaling process in patients with Parkinson’s disease by analyzing theta frequency spectral bands. Background: During…Acute dystonic dyskinesias in a patient used fluvoxamine. Case report
Objective: To represent a case of acute dystonic dyskinesias after fluvoxamine use by the patient with obsessive thoughts and movements. Background: In psychiatric clinical practice,…Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…Genetic Variants and Levodopa Response in Parkinson’s Disease: Insights from MAO-B and DAT1 Polymorphisms
Objective: This study aimed to find the association of genetic variations between Parkinson’s disease (PD) patients with and without levodopa-induced dyskinesia (LID). we intended to…Validation of the Kazakh Version of the Movement Disorder Society-Unified Dyskinesia Rating Scale.
Objective: This study aimed to validate the Kazakh version of the Movement Disorder Society-Unified Dyskinesia Rating Scale Background: The Unified Dyskinesia Rating Scale (UDysRS) has…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 49
- Next Page »